PT Daewoong Pharmaceutical Indonesia has officially launched fexuprazan in Indonesia, introducing a new generation of Potassium-Competitive Acid Blocker (P-CAB) therapy for patients suffering from gastroesophageal reflux disease (GERD).
The product launch took place on Friday, September 18, 2026, during the Indonesian Digestive Disease Week (IDDW) held at the Shangri-La Hotel in Jakarta. The event included a scientific symposium focused on the latest developments in P-CAB therapy and the presentation of clinical evidence regarding the treatment.
Article source: indoposco.id | Image credit: indoposco.id